The running patent dispute between The Liposome Co. Inc. and NeXstar Pharmaceuticals Inc. continued for a second week, with NXTR laying out its defense against anticipated court actions over a patent about to be reissued to LIPO.

NXTR said it has examined the amended patent claims to be included in Patent No. 4,880,635, which the Patent and Trademark Office said it would reissue to LIPO, and concluded that the patent won't have a material impact on its manufacture and sale of AmBisome liposomal amphotericin B.